NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT02536794 2022-05-17
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
Northwestern University
Phase 2 Completed
NCT03608865 2022-01-03
Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing
Yonsei University
Phase 2 Completed
NCT02997995 2020-09-30
ULTIMATE
UNICANCER
Phase 2 Completed